CHA Healthcare: CHA Biotech to buy $58M stake in unit
What's the deal? CHA BiotechDealroom has a profile for this one. Try Dealroom → said on 18 August 2026 it will acquire 2,524,051 shares in its subsidiary CHA Healthcare for 80.3 billion won ($58 million). The off-market purchase is set to close on 10 September 2026.
What changes? Once completed, CHA Biotech's holding in CHA Healthcare will rise to 14,168,288 shares, giving it a 60.1% stake. The purchase equals 7.96% of the company's equity.
Why now? The move follows two CHA Healthcare shareholders — Daishin-Y2HC New Technology Investment Fund No. 1Dealroom has a profile for this one. Try Dealroom → and Hanwha Investment & SecuritiesDealroom has a profile for this one. Try Dealroom → — exercising appraisal rights. CHA Biotech agreed to buy the convertible preferred shares tied to those claims.
The signal: By absorbing the shares put back to it, CHA Biotech tightens control over a core unit — consolidating ownership rather than expanding through outside targets.
Read more: eDaily
Image credit: ell brown
